The Institute for Clinical and Economic Review (ICER) on Thursday, Aug. 15, released its final report on treatments for Duchenne muscular dystrophy (DMD). ICER reviewed three drugs for DMD: PTC Therapeutics' Emflaza and Sarepta Therapeutics' Exondys 51 and golodirsen. ICER CMO David Rind in a […]
ICER to Host Webinar on Sept. 4
The Institute for Clinical and Economic Review (ICER) is set to host a webinar on Sept. 4 to inform participants more about ICER's mission and "proposed enhancements for evaluating medicines and other health care interventions." According to an email, the online event is open to the […]
ICER Plans Review of Sickle Cell Disease Treatments
The Institute for Clinical and Economic Review (ICER) on Aug. 9 announced plans to assess the comparative clinical effectiveness of two treatments for sickle cell disease: Novartis' crizanlizumab and Global Blood Therapeutics' voxelotor. ICER is accepting stakeholder input in preparation for the […]
ICER: Zolgensma Review Not Compromised by Data Issue
The Institute for Clinical and Economic Review (ICER) on Wednesday, Aug. 7, said recent issues with animal testing data for Novartis' Zolgensma will not require an updated review of the initial assessment. The drug pricing watchdog's statement comes on the heels of the Food and Drug […]
ICER Seeks Comments on Value Framework Changes
The Institute for Clinical and Economic Review (ICER) is seeking public feedback on a draft of "proposed adaptations" to its value framework for certain therapies. ICER, according to a press release, will accept comments until 5 p.m. EST Sept. 6. Feedback should be submitted to […]
ICER Holds Public Meeting on DMD Treatments
The Institute for Clinical and Economic Review (ICER) last week held a public meeting on its assessments of Duchenne muscular dystrophy treatments. According to a STAT report, patient advocates in attendance voiced their frustrations as ICER reviewed evidence and discussed whether the price tags […]
AAN’s Winders Discusses Role in ICER’s Reviews on Allergy, Asthma Drugs
The National Pharmaceutical Council recently caught up with Allergy and Asthma Network (AAN) CEO and President Tonya Winders about her role in the Institute for Clinical and Economic Review's (ICER) assessments on allergy and asthma drugs. Winders said she was "ill-prepared" for her first ICER […]
NPR Report Spotlights ICER
A recent report by NPR highlights the increasing influence of an organization which has been branded the "biggest threat" to big pharma: The Institute for Clinical and Economic Review (ICER). The nonprofit drug pricing watchdog has made a name for itself as it produces reports on whether a drug is […]
More on ICER’s Report on DMD Treatments
A recent report by Endpoint News takes a look at the Institute for Clinical and Economic Review's (ICER) recent report on treatments for Duchenne muscular dystrophy. ICER reviewed Sarepta Therapeutics' eteplirsen and golodirsen, as well as PTC Therapeutics' deflazacort. The drug pricing watchdog in […]
ICER Recommends Significant Price Cut for Deflazacort
The Institute for Clinical and Economic Review (ICER) in its latest evidence report on treatments for Duchenne muscular dystrophy suggests that PTC Therapeutics' deflazacort would need to see a roughly 73 percent discount to be cost-effective. ICER in its report reviewed Sarepta Therapeutics' […]
